PharmaSeq

Home Company News & Events Press Releases 2008 NIH Nanotechnology Application Grant

Press Releases

NIH Nanotechnology Application Grant

National Institutes of Health funds Nanotechnology Application at PharmaSeq

Monmouth Junction, NJ, September 22, 2008. PharmaSeq, Inc., announced today the receipt of the Phase I SBIR grant for the project entitled "Use of Silver Nanostructures on Microtransponders in Ultra-sensitive Assays". The grant was awarded by the National Cancer Institute of the NIH. The project is a collaboration with the Fluorescence Commercialization Center of the University of North Texas, Fort Worth, TX.

Dr. Wlodek Mandecki, President of PharmaSeq, Inc., said: "This award underlines the versatility of our microtransponder system that can be adjusted depending on the requirements of a bioassay. We are pleased to be viewed as one of the leading diagnostic R&D companies that are implementing nanotechnology."

The proposed system for an ultra-sensitive assay provides a new tool for performing several tests at once. The system is applicable to cancer diagnostics and other ailments by providing a more powerful, simpler to use and less costly approach. Acceptance of nanotechnology-based multiplex assays on microtransponders by researchers and clinicians could initiate new methods in disease diagnostics and treatment, drug discovery, and biological or environmental research.

The main goal of the project is to increase sensitivity of multiplexed bioassays by introducing a coating containing silver nanostructures on to PharmaSeq's microtransponders in order to enhance fluorescence and improve the detection limit of the test. The key element of the assay is the microtransponder, a small integrated circuit chip that can transmit its identification code by radio frequency. Each microtransponder consists of photocells, read-only memory (ROM), logic circuitry, and an integrated antenna which, when the chip is illuminated, transmits an ID. In an assay, the microtransponders are chemically modified with a molecular probe capable of binding to a fluorescently-labeled analyte of interest. The resulting materials are read in a fluidics-based analyzer that determines the microtransponder serial number and the fluorescence intensity to provide information about molecular interactions in the bioassay.

For further information, please contact Dr. Richard Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100 ext 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852
Find us on the web at: www.pharmaseq.com.

Home Company News & Events Press Releases 2008 NIH Nanotechnology Application Grant